Mirikizumab demonstrates consistent and sustained disease clearance at four years of treatment in patients with moderately to severely active ulcerative colitis

F Magro, S Danese, B Siegmund, T Kobayashi, C Siegel, V Jairath, P Pellanda, A Keohane, Y Duan, R Arora, I Redondo, J-F Colombel · Zeitschrift für Gastroenterologie · 2026 · Heft 08 · S. e316